Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1380 • ACR Convergence 2024
Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib
Manish Jain¹, Arthur Kavanaugh², Angela Crowley³, Avani Joshi⁴, Patrick Zueger⁵, Diane Caballero⁶, Andrew Garrison⁶ and Peter C. Taylor⁷, ¹Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, ²University of California San Diego, La Jolla, CA, ³Illinois Bone and Joint Institute, Hinsdale Orthopaedics, Hinsdale, IL, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc, North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: Pain is a crucial symptom for patients with RA; early and effective treatment can help alleviate it.1 In this post hoc analysis, we investigated…
Abstract Number: 1397 • ACR Convergence 2024
Temporal Trends in Early Rheumatoid Arthritis (ERA) Patients with Moderate to Severe Disease Activity: A Multicenter Cohort Study of Treatment Strategies and Outcomes in Chinese Patients in the Modern Era
Yafang Deng¹, Chen Yu², Lin Qiao¹, Nan Jiang¹, Yanhong Wang³, Xinping Tian¹, Qian Wang¹, Mengtao Li⁴ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ³Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China
Background/Purpose: In the contemporary era, the continuous update of international rheumatoid arthritis (RA) guidelines has significantly impacted the diagnosis and management of RA patients in…
Abstract Number: 1673 • ACR Convergence 2024
Assessing the Feasibility of a Mediterranean-Style Diet for Patients with Rheumatoid Arthritis in a Racially and Culturally Diverse Population Across the United States
Chelsea Thompson¹, iazsmin Ventura¹, Cuoghi Edens², Tamiko Katsumoto³ and Sowmya Popuri⁴, ¹Section of Rheumatology, University of Chicago, Chicago, IL, ²Section of Pediatric Rheumatology, Section of Rheumatology, University of Chicago, Chicago, IL, ³Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Section of Internal Medicine, Loyola Medicine MacNeal, Maywood, IL
Background/Purpose: In 2023, the American College of Rheumatology published a conditional recommendation for patients living with Rheumatoid Arthritis to follow a “Mediterranean style” diet. However,…
Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Parmita Das¹, Snehin Rajkumar², Eric Yen³ and Ram Singh⁴, ¹University of California Los Angeles, Saint Johns, ²UCLA David Geffen School of Medicine, Irvine, CA, ³UCLA, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…
Abstract Number: 1882 • ACR Convergence 2024
30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database
Shobhit Piplani¹, Priyanshu Jain², Vladimir Jelic³, Clement Tagoe⁴ and Beverly Johnson⁵, ¹Jacobi Medical Center/North Central Bronx Albert Einstein College of Medicine NYC Health and Hospitals, Bronx, NY, ²Jawaharlal Nehru Medical College, Belgaum, Karnataka, India, Bronx, NY, ³Jacobi Medical Center/North Central Bronx, Bronx, NY, ⁴Albert Einstein College of Medicine, FRESH MEADOWS, NY, ⁵Albert Einstein College of Medicine, New York, NY
Background/Purpose: Rheumatoid Arthirits (RA) is associated with heightened morbidity, diminished quality of life, and increased healthcare expenses. This research aims to bridge this gap by…
Abstract Number: 1968 • ACR Convergence 2024
Development and Validation of an Arthritis-Detection Algorithm Using Thermal Imaging in Adults and Children
Thomason Jenna¹, Sullivan Erin², Rajdeep Pooni³, Liau Adriel⁴, Sadie Van den Bogaerde⁵, Audrey Luey⁶, Iris Hamilton⁷, Sriya Paluvayi⁶, Megan Tran¹, Janeth Robles-Navarro¹, Ian Muse⁸, Ava Klein⁴, Tzielan Lee⁹, Grant Hughes⁵, Alison Bays⁵, Elizabeth Ferucci¹⁰, Debosmita Biswas¹¹, Savannah Patridge¹¹ and Yongdong (Dan) Zhao¹², ¹University of Washington, Division of Rheumatology, Seattle, WA, ²Biostatistics, Epidemiology, and Analytics in Research (BEAR) Core, Seattle Children’s Research Institute, Seattle, WA, ³Stanford University, Palo Alto, CA, ⁴Seattle Children’s Research Institute, University of Washington, Seattle, ⁵University of Washington, Seattle, WA, ⁶Seattle Children’s Research Institute, University of Washington, Seattle, WA, ⁷Seattle Children's Hospital, Seattle, ⁸Seattle Children's Research institute, Seattle, WA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Alaska Native Tribal Health Consortium, Anchorage, AK, ¹¹University of Washington, Department of Radiology, Seattle, WA, ¹²University of Washington, Redmond, WA
Background/Purpose: The Thermal imaging-based Temperature After Within-limb Calibration (TAWiC) algorithm for the detection of arthritis in the knees has been validated in children by our…
Abstract Number: 2210 • ACR Convergence 2024
Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality
Rebecca Brooks¹, Sara Achenbach², Vanessa Kronzer¹, Elena Myasoedova¹, Cynthia Crowson¹ and John Davis¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Both RF and anti-CCP are associated with erosive disease, increased disease activity, and adverse outcomes in RA. However, there have been limited studies investigating how…
Abstract Number: 2228 • ACR Convergence 2024
Feasibility, Safety, and Application for Clinical Indication and Research Purposes of Synovial Tissue Analysis in Rheumatoid Arthritis
VAN MULLEM Cécile¹, VIAILLE Charlotte¹, DIERCKX Stéphanie², NATALUCCI Francesco³, Clément triaille⁴, SAPART Emilie¹, de MONTJOYE Stéphanie¹, SOKOLOVA Tatiana¹, AVRAMOVSKA Aleksandra¹, NZEUSSEU TOUKAP Adrien⁵, MERIC de BELLEFON Laurent¹ and DUREZ Patrick¹, ¹Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Bruxelles, Belgium, ³Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, ⁴Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, ⁵Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: The development of ultrasound-guided synovial biopsy (US-SB) in addition to the knee mini-arthroscopy enabled synovial tissue collection from small and medium joints and facilitated molecular studies. This technique will…
Abstract Number: 2244 • ACR Convergence 2024
Unveiling Synovial Protein Contributions to Serum Inflammation, Disease Activity, and Treatment Outcomes in RA Patients
Chary Lopez-Pedrera¹, Sagrario Corrales², Julio Osuna³, Rafaela Ortega-Castro⁴, Jerusalén Calvo³, María Lourdes Ladehesa-Pineda¹, Ismael Sánchez Pareja², Laura Muñoz-Barrera², Desiree Ruiz-Vilchez³, Christian Merlo⁵, Mª Angeles Aguirre-Zamorano⁶, Nuria Barbarroja², Tomás Cerdó², Rosa ortega³, Marta Alarcon-Riquelme⁷, Carlos Perez-Sanchez², Alejandro Escudero-Contreras² and Concepción Aranda-Valera⁸, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁵Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁷Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain
Background/Purpose: Characterize synovial tissue-secreted proteins in RA patients that contibute to serum inflammatory profiles based on immune cell infiltration.Identify RA patient subsets with distinctive serum…
Abstract Number: 2264 • ACR Convergence 2024
The Risk of Malignancy and Major Adverse Cardiovascular Events with the Use of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Real-World Evidence
Majeed Haider¹, Osama Alalwan² and Helen Harris³, ¹Salmaniya Medical Complex, Manama, Bahrain, ²Salmaniya Medical Complex, Bahrain, Bahrain, ³NHS Lothian, Western General Hospital, Edinburgh, Scotland, United Kingdom
Background/Purpose: Tofacitinib is the first Janus Kinase Inhibitor (JAKi) approved for treating adults with rheumatoid arthritis (RA). Recently, its use has been linked to an…
Abstract Number: 2282 • ACR Convergence 2024
Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response
M. Elaine Husni, Judy Zhang, Jean Lin, Yuxuan Jin and Unnikrishnan Chandrasekharan, Cleveland Clinic, Cleveland, OH
Background/Purpose: The development of a personalized medicine approach to identify responders and non-responders to tumor necrosis factor alpha (TNFα) inhibiting agents for rheumatoid arthritis (RA)…
Abstract Number: 2566 • ACR Convergence 2024
Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
andriko Palmowski¹, Zhivana Boydzhieva², Paula Hoff³, Sandra Hermann³, burkhard Muche³, David Simon⁴, Gerhard Krönke³, Edgar Wiebe⁵ and FRANK HARTMUT DR. BUTTGEREIT⁵, ¹Charité - Universittsmedizin Berlin, Berlin, Germany, ²Charité Universittsmedizin, Berlin, Germany, ³Rheumatology, Charité, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: In a previous study, we found daily proton pump inhibitor (PPI) intake to be associated with decreased bone mineral density in patients with inflammatory…
Abstract Number: 2674 • ACR Convergence 2024
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States
christina Charles-Schoeman¹, Patrick Zueger², Erin Blondell², Siran Fang², Yi Peng², Manish Jain³ and John Tesser⁴, ¹UCLA Medical Center, Santa Monica, CA, ²AbbVie Inc, North Chicago, IL, ³Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, ⁴Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ
Background/Purpose: For patients with rheumatoid arthritis (RA), current ACR guidelines recommend evaluating treatment response within 3 months of initiating a new therapy. In patients who…
Abstract Number: 0007 • ACR Convergence 2024
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Ryota Sato¹, Mitsuhiro Akiyama², Koichi Oshita³, Yuko Kawano³, Yuki Imura³, Piruzyan Mariam⁴, Manami Kikuchi³, Mikako Murase³, Sachiko Mochiduki³, Naohiro Hashimoto³, Masayuki Watanabe³, Keiko Yoshimoto⁵, Tsutomu Takeuchi⁶, Kenji Chiba⁷ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Brighton, MA, ²Keio University School of Medicine, Palo Alto, CA, ³Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ⁴Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
Abstract Number: 0046 • ACR Convergence 2024
Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies
Jeba Atkia Maisha¹, Alina Sememenko², Jun Kim², Mario Navarrete², XIAOBO MENG¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, Canada
Background/Purpose: Rheumatoid Arthritis (RA) begins after a prolonged preclinical phase which is marked by the development of RA antibodies, typically against citrullinated proteins (ACPA). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].